Nasdaq
$1.93▲ 0.78%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $31.4MShares out 16.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
28- 3d agoAfter-hours26.10.22 07:064Ownership#●●●
Grace Therapeutics, Inc.
Opaleye Management Inc., a major shareholder of Grace Therapeutics, reported a change in its beneficial ownership of company shares as of October 19, 2026. This filing is a Form 4 statement detailing the change in holdings by an insider or major shareholder.…more
$1.93+0.78%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.17Closed26.10.17 09:424Ownership
Grace Therapeutics, Inc.
Opaleye Management Inc. has filed a Form 4 regarding a change in its beneficial ownership of Grace Therapeutics, Inc. securities. The transaction occurred on October 14, 2026.…more
$1.93+0.78%vs prev closeView filingShare - 10.13After-hours26.10.14 06:454Ownership
Grace Therapeutics, Inc.
Opaleye Management Inc., an insider of Grace Therapeutics, Inc., reported a change in beneficial ownership of securities as of October 8, 2026. This filing serves as an official notification to the SEC regarding the insider's transaction.…more
$1.93+0.78%vs prev closeView filingShare
27 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 8.24After-hours26.08.25 05:12Bullish#●●●
Grace Therapeutics Files Prospectus For Offering 4.762M Common Shares
Grace Therapeutics has filed a prospectus for the sale of 4.762 million common shares by selling shareholders. This secondary offering may lead to potential share dilution and increased selling pressure.…more
$1.93+0.78%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 8.13Pre-market26.08.13 21:00
●●●●●●●● ●●●●● ●●●●●●
Grace Therapeutics is pursuing a dual-source manufacturing strategy to address FDA requirements for its GTx-104 new drug application. The company also secured $10 million in financing, extending its operational runway through 2028.…more
$1.93+0.78%vs prev close - 8.5Overnight26.08.05 10:00
●●●●●●●● ●●●●● ●●●●●●
그레이스 테라퓨틱스가 신약 후보물질 GTx-104의 제조 및 규제 대응 자금 확보를 위해 1,000만 달러 규모의 유상증자를 결정했습니다. 이번 자금 조달로 2028년 말까지 운영 자금을 확보했으나, 신주 발행에 따른 주식 가치 희석은 투자자가 고려해야 할 요소입니다.…more
$1.93+0.78%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report